Medical Advisory Board
At CR&T, our activities and funding objectives are guided by the expertise of our Medical Advisory Board (MAB), comprising some of the world’s foremost physician-scientists specializing in cancer research.
Advisory board members are widely recognized for their contributions to research in various types of blood cancers, including the myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease, and multiple myeloma. Other MAB members are known for their contributions to breast and lung cancer.
The current CR&T Medical Advisory Board members are:
- Ghaith Abu-Zeinah, MD, Weill Cornell Medicine
- Edward P. Ambinder, MD, Icahn School of Medicine at Mount Sinai
- Morton Coleman, MD, FACP, New York-Presbyterian Hospital and Weill Cornell Medicine
- John P. Leonard, MD, New York-Presbyterian Hospital and Weill Cornell Center for Lymphoma and Myeloma
- Anne Moore, MD, Weill Cornell Breast Center
- Malcolm Moore, DPhil, Memorial Sloan Kettering Cancer Center
- Mark Pasmantier, MD, NewYork-Presbyterian Hospital and Weill Cornell Medical College
- Shahin Rafii, MD, Weill Cornell Medicine
- Joseph M. Scandura, MD, PhD, Weill Cornell Medicine
- Andrew I. Schafer, MD, Director, Richard T. Silver, MD Center for Myeloproliferative Neoplasms at Weill Cornell Medicine
- David A. Scheinberg, MD, PhD, Memorial Sloan Kettering Cancer Center
- Richard T. Silver, MD, FACP, Weill Cornell Medicine and CR&T Vice President, Medical Director
- Jerry L. Spivak, MD, Johns Hopkins University School of Medicine
- Alexander J. Swistel, MD, Weill Cornell Breast Center